

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C. 20549Form 6-KREPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGEACT OF
1934For the month of October 2024Commission File Number: 001-35165BRAINSWAY LTD.(Translation of
registrant'sname into English)16 Hartum Street RAD Tower, 14th Floor Har HaHotzvim Jerusalem,
9777516,Israel(+972-2) 582-4030 (Address and telephone number of Registrant's principal executive
office)Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form
40-F. Form 20-F[X] Form 40-F []This Form 6-K is incorporated by reference into the Company's
Registration Statement on Form S-8 filed with the Securities and ExchangeCommission on April 22, 2019 (Registration
No. 333-230979) and the Company's Registration Statement on Form F-3 filed with the Securitiesand Exchange
Commission on July 22, 2024 (Registration No. 333-280934). EXHIBIT INDEXÂ Exhibit Â Title Â 99.1 Â
BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMSâ„¢ Systems in Taiwan and South
Korea SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on itsbehalf by the undersigned, thereunto duly authorized. Â BRAINSWAY
LTD.Â (Registrant) Â Date: October 9, 2024 Â /s/ Hadar Levy Â Hadar Levy
Â Chief Executive Officer Â Edgar Filing EXHIBIT 99.1 BrainsWay Further Penetrates East Asia with Placement
of 15 AdditionalDeep TMSâ„¢ Systems in Taiwan and South KoreaBURLINGTON, Mass. and JERUSALEM, Israel, Oct.
09, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY)(âœ BrainsWayâ€ or the âœ Companyâ€),
a global leader in advanced noninvasive neurostimulation treatments for mentalhealth disorders, today announced the
further expansion of its Deep Transcranial Magnetic Stimulation (Deep TMSâ„¢) platform in EastAsia through the
placement of 15 new systems in Taiwan and South Korea.âœ The recent orders for 15 additional Deep TMS systems to
be used by mental health centers in Taiwan and SouthKorea are indicative of the continued commercial success we are
experiencing in penetrating this strategically important region. Thesecountries each play an important role in our
international growth strategy, and we are pleased to report the expanding demand from theEast Asia region,â€ said
Hadar Levy, BrainsWayâ€'s Chief Executive Officer. âœ The BrainsWay team and our international
distributionpartners continue to focus on expanding access to our innovative Deep TMS platform among patients and
healthcare providers globally.âœ About BrainsWayBrainsWay is a global leader in advanced noninvasive
neurostimulation treatments for mental health disorders. The Companyis boldly advancing neuroscience with its
proprietary Deep Transcranial Magnetic Stimulation (Deep TMSâ„¢) platform technology to improvehealth and
transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal
clinicalstudies demonstrating clinically proven efficacy. Current indications include major depressive disorder
(including reduction of anxietysymptoms, commonly referred to as anxious depression), obsessive-compulsive disorder,
and smoking addiction. The Company is dedicatedto leading through superior science and building on its unparalleled
body of clinical evidence. Additional clinical trials of Deep TMSin various psychiatric, neurological, and addiction
disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem,Israel, BrainsWay is committed
to increasing global awareness of and broad access to Deep TMS. For the latest news and information aboutBrainsWay,
please visit www.brainsway.com.Forward-Looking StatementThis press release contains âœforward-looking
statementsâ€ within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such statements may be
preceded by the words âœintends,â€ âœmay,â€ âœwill,â€ âœplans,â€ âœexpects,â€ âœanticipates,â€
âœprojects,â€ âœpredicts,â€ âœestimates,â€ âœaims,â€ âœbelieves,â€ âœhopes,â€ âœpotentialâ€ or similar
words. These forward-looking statementsinclude, among others, statements regarding the completion of the offering,
the satisfaction of customary closing conditions related tothe offering, the anticipated use of proceeds therefrom, the
ability of the Company to obtain shareholder approval, and the exercise ofthe Warrants prior to their expiration, and
their implications are based on the current expectations of the management of the Companyonly and are subject to a
number of factors and uncertainties that could cause actual results to differ materially from those describedin the
forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do
notguarantee that future results would suggest similar conclusions or that historical results referred to herein would be
interpreted similarlyin light of additional research or otherwise. The following factors, among others, could cause actual
results to differ materially fromthose described in the forward-looking statements: market and other conditions,
inadequacy of financial resources to meet future capitalrequirements; changes in technology and market requirements;
delays or obstacles in launching and/or successfully completing planned studiesand clinical trials; failure to obtain
approvals by regulatory agencies on the Companyâ€'s anticipated timeframe, or at all; inabilityto retain or attract key
employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties withDeep
TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep
TMS products; failureto obtain and maintain adequate protection of the Companyâ€'s intellectual property, including
intellectual property licensed to theCompany; the potential for product liability; changes in legislation and applicable
rules and regulations; unfavorable market perceptionand acceptance of Deep TMS technology; inadequate or delays in
reimbursement from third-party payers, including insurance companies andMedicare; inability to commercialize Deep
TMS, including internationally, by the Company or through third-party distributors; productdevelopment by
competitors; inability to timely develop and introduce new technologies, products and applications, which could cause
theactual results or performance of the Company to differ materially from those contemplated in such forward-looking
statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The
Companyundertakes no obligation to publicly update or review any forward-looking statement, whether as a result of
new information, future developmentsor otherwise, except as may be required by any applicable securities laws. More
detailed information about the risks and uncertaintiesaffecting the Company is contained under the heading âœRisk
Factorsâ€ in the Companyâ€'s filings with the U.S. Securitiesand Exchange Commission. Contacts:Â BrainsWay: Ido
MaromChief Financial Officer Ido.Marom@BrainsWay.com Investors: Brian RitchieLifeSci Advisors
LLCbritchie@lifesciadvisors.com